Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Allocetra-OTS in advanced solid tumors
NCT05581719Phase 2Terminated
- Sponsor
- Enlivex Therapeutics
- Start
- Nov 2022
- Primary completion
- Apr 2024
- Modality
- Cell Therapies
- Countries
- 2
01
Overview
Phase 2, open-label trial of Allocetra in solid tumor and primary peritoneal cancer (PPC) (3 arms), sponsored by Enlivex Therapeutics. Primary endpoint: Safety of Allocetra-OTS. Started Nov 2022; status: terminated.
02
Drugs
Allocetra
03
Conditions
solid tumorprimary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT05581719.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05581719.